Published in J Clin Oncol on June 18, 2012
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol (2014) 3.04
A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature (2015) 1.66
Breast cancer as a systemic disease: a view of metastasis. J Intern Med (2013) 1.55
Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol (2014) 1.28
Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol (2013) 1.16
The AURORA initiative for metastatic breast cancer. Br J Cancer (2014) 1.15
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med (2013) 1.14
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2015) 1.11
The tumor microenvironment controls drug sensitivity. Nat Med (2012) 1.05
Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med (2012) 1.04
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res (2014) 1.01
Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Eur J Nucl Med Mol Imaging (2013) 0.96
Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer (2016) 0.96
Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol (2013) 0.95
Next-generation sequencing of disseminated tumor cells. Front Oncol (2013) 0.94
Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist (2013) 0.94
Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov (2013) 0.91
Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res (2014) 0.91
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? Front Pharmacol (2016) 0.91
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol (2014) 0.90
Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist (2014) 0.89
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT. Theranostics (2016) 0.89
Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation. Onco Targets Ther (2014) 0.87
AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. Breast Care (Basel) (2013) 0.87
The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation. Oncogene (2014) 0.86
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget (2015) 0.85
Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Breast Care (Basel) (2015) 0.85
Targeting Breast Cancer Metastasis. Breast Cancer (Auckl) (2015) 0.85
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist (2015) 0.84
Interleukin-19 in breast cancer. Clin Dev Immunol (2013) 0.84
Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification? Oncologist (2014) 0.84
Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer. J Exp Clin Cancer Res (2014) 0.84
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol (2015) 0.83
A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. J Transl Med (2015) 0.83
Cell cycle dependent oscillatory expression of estrogen receptor-α links Pol II elongation to neoplastic transformation. Proc Natl Acad Sci U S A (2014) 0.82
The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. World J Surg Oncol (2014) 0.82
Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis. J Breast Cancer (2016) 0.82
Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. Oncogene (2015) 0.82
A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer (2012) 0.82
History, biology, and health inequities: emergent embodied phenotypes and the illustrative case of the breast cancer estrogen receptor. Am J Public Health (2012) 0.80
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol (2015) 0.80
Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study. J Histochem Cytochem (2016) 0.80
Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases. Clin Proteomics (2015) 0.80
High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers. J Breast Cancer (2017) 0.79
Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. Am J Nucl Med Mol Imaging (2016) 0.79
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. Oncotarget (2016) 0.78
Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep (2013) 0.78
Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. BMC Cancer (2013) 0.78
Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. Eur J Nucl Med Mol Imaging (2014) 0.77
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis (2016) 0.77
Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing. Oncotarget (2015) 0.76
Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. PLoS One (2016) 0.76
The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization. Curr Breast Cancer Rep (2014) 0.76
The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol (2015) 0.76
Changes in intrinsic subtype of breast cancer during tumor progression in the same patient. Int J Clin Exp Pathol (2015) 0.75
Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol (2013) 0.75
Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers. Oncologist (2017) 0.75
Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget (2016) 0.75
The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case. Oncoscience (2016) 0.75
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. BMC Cancer (2014) 0.75
Improving systemic breast cancer therapy: time to look beyond the primary tumour? Facts Views Vis Obgyn (2015) 0.75
Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel. J Vasc Interv Radiol (2015) 0.75
Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Oncotarget (2016) 0.75
The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT. Nucl Med Mol Imaging (2016) 0.75
Conditional disease-free survival among patients with breast cancer. Medicine (Baltimore) (2017) 0.75
Receptor conversion in metastatic breast cancer: a prognosticator of survival. Oncotarget (2016) 0.75
Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Oncotarget (2017) 0.75
Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget (2017) 0.75
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. Eur J Nucl Med Mol Imaging (2017) 0.75
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Estrogen receptors: how do they signal and what are their targets. Physiol Rev (2007) 5.27
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res (2007) 3.51
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 2.64
Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A (2004) 2.64
Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res (2005) 2.48
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol (2012) 2.45
Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics (2008) 2.08
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res (2006) 2.02
Low concordance of biomarkers in histopathological and cytological material from breast cancer. Histopathology (2014) 1.96
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics (2005) 1.86
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol (2009) 1.81
Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr (2009) 1.79
Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol (2007) 1.68
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res (2011) 1.67
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.66
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol (2006) 1.52
Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause (2007) 1.50
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol (2009) 1.46
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast (2009) 1.42
Diagnosis and grading of chondrosarcomas on FNA biopsy material. Diagn Cytopathol (2003) 1.41
Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res (2003) 1.41
[Diagnostic problems in hypothyroidism: is increased lymphocyte count in fine needle biopsy an indication for treatment?]. Lakartidningen (2006) 1.40
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat (2010) 1.31
Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res (2011) 1.30
Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat (2010) 1.27
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol (2010) 1.23
Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol (2005) 1.22
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat (2010) 1.20
High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One (2013) 1.19
Improvements in patient satisfaction at an outpatient clinic for patients with breast cancer. Acta Oncol (2006) 1.16
Prevalence of childhood celiac disease and changes in infant feeding. Pediatrics (2013) 1.15
Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom-in array comparative genomic hybridization (aCGH). Hum Mutat (2008) 1.15
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat (2010) 1.13
Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst (2009) 1.13
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin Chem (2004) 1.13
Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res (2010) 1.12
Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res (2007) 1.11
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat (2012) 1.10
A methodological report from the Malmö Diet and Cancer study: development and evaluation of altered routines in dietary data processing. Nutr J (2002) 1.09
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst (2005) 1.09
Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol (2012) 1.09
Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med (2006) 1.08
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis (2003) 1.07
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland. Hum Mutat (2003) 1.07
Postmenopausal breast cancer is associated with high intakes of omega6 fatty acids (Sweden). Cancer Causes Control (2002) 1.05
Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res (2010) 1.05
Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys (2007) 1.03
The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol (2007) 1.03
Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res (2012) 1.02
Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients. Clin Cancer Res (2009) 1.02
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res (2010) 1.01
Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care. Acta Oncol (2004) 0.99
Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med (2014) 0.99
How to treat male breast cancer. Breast (2007) 0.99
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol (2008) 0.99
Individual psychosocial support for breast cancer patients: a randomized study of nurse versus psychologist interventions and standard care. Cancer Nurs (2007) 0.98
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res (2013) 0.97
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat (2011) 0.96
Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer (2003) 0.95
Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer (2006) 0.95
Balancing health benefits and social sacrifices: a qualitative study of how screening-detected celiac disease impacts adolescents' quality of life. BMC Pediatr (2011) 0.95
A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma (2002) 0.95
Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene (2003) 0.94